First Light Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

First Light Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-848,477	Closed	-$17M	–	83
2023 Q3	$17M	Buy	848,477 +90,642	+12%	+$2.3M	1.62%	25
2023 Q2	$21.4M	Buy	+757,835	New	+$18.2M	1.68%	20

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

First Light Asset Management's ZNTL Position: Q4 2023 in Review

First Light Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2023, closing a stake of 848,477 shares — an estimated $17M sold.

First Light Asset Management first reported a position in ZNTL in Q2 2023 and held it in 2 quarters. The position peaked at $21.4M in Q2 2023. 120 funds tracked by Wall St. Rank hold ZNTL as of Q4 2023.

First Light Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
First Light Asset Management sold 848,477 Zentalis Pharmaceuticals shares in Q4 2023, an estimated $17M.
First Light Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 2 quarters.
First Light Asset Management's Zentalis Pharmaceuticals position peaked at $21.4M in Q2 2023.
120 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2023.

Based on First Light Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.